{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-004328","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.314299+00:00","generated_at":"2026-06-17T17:13:41.166870+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MAIA Biotechnology reports 2022 net loss of $15.7M; cash $10.9M; Phase 2 NSCLC trial underway in Europe","bullets":["Net loss $15.7M for 2022 vs $12.6M in 2021; R&D expenses $8.9M (up from $3.5M) due to THIO trial startup.","Cash $10.9M at Dec 31, 2022 vs $10.6M at Dec 31, 2021; G&A expenses $6.1M (up from $4.3M) including $1.1M ratchet share expense.","First two patients dosed in Phase 2 THIO-101 trial in Europe for advanced NSCLC; plan to initiate second Phase 2 trial THIO-102.","Pre-IND meeting with FDA for U.S. expansion; positive feedback on manufacturing and clinical development plan.","Preclinical data presented at SITC for THIO in hepatocellular carcinoma; new telomere-targeting molecule program advanced."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-004328","json":"https://secwatch.observer/filing/0001564590-23-004328.json","markdown":"https://secwatch.observer/filing/0001564590-23-004328.md","text":"https://secwatch.observer/filing/0001564590-23-004328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023004328/0001564590-23-004328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023004328/maia-8k_20230324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T17:13:41.166870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4256c72edc57a80f41e0597d8124ed36679deed8","claim":"MAIA Biotechnology, Inc. reported for the year ended December 31, 2022 results: net income approximately $15.7 million.","evidence_excerpt":"Net loss was approximately $15.7 million for the year ended December 31, 2022, as compared to net loss of approximately $12.6 million for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023004328/0001564590-23-004328-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2022"},{"label":"Net income","value":"approximately $15.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}